肌萎缩侧索硬化
腺相关病毒
遗传增强
基因沉默
医学
疾病
SOD1
基因
C9orf72
RNA干扰
神经科学
生物信息学
生物
遗传学
病理
核糖核酸
失智症
载体(分子生物学)
痴呆
重组DNA
作者
Katharina E. Meijboom,Robert H. Brown
标识
DOI:10.1007/s13311-022-01285-w
摘要
Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease for which there is currently no robust therapy. Recent progress in understanding ALS disease mechanisms and genetics in combination with innovations in gene modulation strategies creates promising new options for the development of ALS therapies. In recent years, six gene modulation therapies have been tested in ALS patients. These target gain-of-function pathology of the most common ALS genes, SOD1, C9ORF72, FUS, and ATXN2, using adeno-associated virus (AAV)-mediated microRNAs and antisense oligonucleotides (ASOs). Here, we review the latest clinical and preclinical advances in gene modulation approaches for ALS, including gene silencing, gene correction, and gene augmentation. These techniques have the potential to positively impact the direction of future research trials and transform ALS treatments for this grave disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI